/AMGEN%20Inc_%20logo%20on%20phone-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
Thousand Oaks, California-based Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $142 billion, Amgen has been a pioneer in the biotechnology industry for over 40 years. Its portfolio includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.
The drug manufacturer is expected to announce its fourth-quarter results on Tuesday, Feb. 4. Ahead of the event, analysts expect AMGN to report a non-GAAP profit of $5.02 per share, up 6.6% from $4.71 per share reported in the year-ago quarter. The company has a robust earnings surprise history. It has surpassed Wall Street’s bottom-line estimates in each of the past four quarters. Amgen’s adjusted EPS for the last reported quarter surged 12.5% year-over-year to $5.58, exceeding analysts’ estimates by 9.2%.